Extensions

U.S. Patent 11,644,693: Term,Continuity, and Family Analysis

As a senior patent analyst, the following provides a detailed breakdown of the term, application history, and related patents for U.S. Patent No. 11,644,693 (the '693 patent).

Patent Term and Expiration

• Filing Date: The application for the '693 patent (No. 17/873,104) was filed on July 25, 2022.
• Patent Term Adjustment (PTA): There is no record of any Patent Term Adjustment (PTA) for this patent. PTA is granted to compensate for certain administrative delays by the U.S. Patent and Trademark Office (USPTO) during prosecution. The absence of PTA indicates the patent was issued within the standard timeframes set by the USPTO.
• Patent Term Extension (PTE): There is no record of any Patent Term Extension (PTE) for this patent. PTE is typically granted for patents covering products that have undergone a lengthy regulatory review process (e.g., by the FDA) and is not applicable in this case.
• Projected Expiration Date: Based on its earliest non-provisional priority date of July 15, 2005, and the standard 20-year patent term, the projected expiration date for U.S. Patent No. 11,644,693 is July 15, 2025. This date has been noted in public patent information databases.

Continuity and Application History

The '693 patent is part of a larger family of patents and applications, indicating a long history of development and a strategic approach to protecting the technology. This is established through a chain of "continuation" and "divisional" applications.

• Parent Applications: The '693 patent is a continuation of U.S. Patent Application No. 17/307,645 (now U.S. Patent No. 11,422,382), which itself is a continuation of a series of earlier applications. Tracing back the priority claims reveals the following key parent applications:

  • Direct Parent: U.S. Application No. 17/307,645, filed May 4, 2021 (now U.S. Patent No. 11,422,382).
  • Grandparent: U.S. Application No. 16/167,745, filed October 23, 2018 (now U.S. Patent No. 10,996,448).
  • And so on, ultimately claiming priority back to: U.S. Application No. 11/183,269, filed on July 15, 2005 (now U.S. Patent No. 7,922,321). This is the earliest non-provisional application in the chain and thus sets the 20-year term for all subsequent patents in this family.

• Continuation Applications: The strategy of filing a series of continuation applications allows an inventor to pursue claims to different aspects of the originally disclosed invention in separate patents. This is a common practice to build a broad and robust patent portfolio.

• Divisional Applications: While not explicitly listed for the '693 patent itself, divisional applications are another tool used to pursue distinct inventions that may have been disclosed in a single original application.

Patent Family Members

The '693 patent belongs to a large family of related U.S. patents and patent applications assigned to Ingeniospec LLC. These patents all share a common priority date and cover various aspects of integrating electronics into eyewear. Notable members of this family include:

• U.S. Patent No. 7,922,321
• U.S. Patent No. 10,996,448
• U.S. Patent No. 11,422,382
• U.S. Patent No. 11,921,355
• U.S. Patent No. 12,140,819

This extensive patent family indicates a long-term and strategic effort by the assignee to protect innovations in the field of "smart" eyewear and wearable audio devices. The existence of numerous related patents strengthens Ingeniospec's position in licensing negotiations and litigation by covering a wide range of features and implementations.